{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:13:46Z","timestamp":1761743626730},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.nbd.2012.04.004","type":"journal-article","created":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T08:00:26Z","timestamp":1334563226000},"page":"153-178","source":"Crossref","is-referenced-by-count":25,"title":["Translating the therapeutic potential of neurotrophic factors to clinical \u2018proof of concept\u2019: A personal saga achieving a career-long quest"],"prefix":"10.1016","volume":"48","author":[{"given":"Raymond T.","family":"Bartus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2012.04.004_bb0020","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm0696-696","article-title":"Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients","volume":"2","author":"Aebischer","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2012.04.004_bb0005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0074-7742(02)50083-0","article-title":"Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?","volume":"50","author":"Apfel","year":"2002","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.51.3.695","article-title":"Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy","volume":"51","author":"Apfel","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2012.04.004_bb0010","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.284.17.2215","article-title":"Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial","volume":"284","author":"Apfel","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.nbd.2012.04.004_bb0025","doi-asserted-by":"crossref","first-page":"10410","DOI":"10.1523\/JNEUROSCI.2541-04.2004","article-title":"Chronic back pain is associated with decreased prefrontal and thalamic gray matter density","volume":"24","author":"Apkarian","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0030","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0197-4580(88)80142-8","article-title":"Use of tissue culture models to study neuronal regulatory trophic and toxic factors in the aged brain","volume":"9","author":"Azmitia","year":"1988","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2012.04.004_bb0040","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1523\/JNEUROSCI.16-17-05437.1996","article-title":"Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy","volume":"16","author":"Backman","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-9861(19971013)387:1<1::AID-CNE1>3.0.CO;2-5","article-title":"Carrier mediated delivery of NGF: alterations in basal forebrain neurons in aged rats revealed using antibodies against low and high affinity NGF receptors","volume":"387","author":"Backman","year":"1997","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0580","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ymthe.2006.05.005","article-title":"Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC","volume":"14","author":"Bankiewicz","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0140","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0197-4580(88)80097-6","article-title":"The need for common perspectives in the development and use of animal models for age-related cognitive and neurodegenerative disorders","volume":"9","author":"Bartus","year":"1988","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.nbd.2012.04.004_bb0135","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0197-4580(89)90117-6","article-title":"Neurotrophic factors: can the degenerating brain be induced to heal itself?","volume":"10","author":"Bartus","year":"1989","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.nbd.2012.04.004_bb0130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0197-4580(89)90154-1","article-title":"Drug delivery to the brain: the problem lurking behind the problem?","volume":"10","author":"Bartus","year":"1989","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.nbd.2012.04.004_bb0585","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/107385849700300513","article-title":"The Calpain hypothesis of neurodegeneration: evidence for a common cytotoxic pathway","author":"Bartus","year":"1997","journal-title":"Neuroscientist"},{"key":"10.1016\/j.nbd.2012.04.004_bb0100","first-page":"152","article-title":"The blood\u2013brain barrier as a target for pharmacological modulation","volume":"2","author":"Bartus","year":"1999","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.nbd.2012.04.004_bb0090","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/exnr.2000.7397","article-title":"On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis","volume":"163","author":"Bartus","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00213-008-1365-7","article-title":"Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps","volume":"202","author":"Bartus","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.nbd.2012.04.004_bb0150","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.nbd.2012.04.004_bb0590","series-title":"Banbury Report 1515: Biological Aspects of Alzheimer's Disease","first-page":"207","article-title":"Behavioral and pharmacological studies using animal models of aging: implications for studying and treating dementia of Alzheimer's type","author":"Bartus","year":"1983"},{"key":"10.1016\/j.nbd.2012.04.004_bb0115","first-page":"49","article-title":"Dissociation of p75 receptors and nerve growth factor neurotrophic effects: lack of p75 immunoreactivity in striatum following physical trauma, excitotoxicity and NGF administration","volume":"10","author":"Bartus","year":"1996","journal-title":"Restor. Neurol. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0162-3109(96)00070-7","article-title":"Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system","volume":"33","author":"Bartus","year":"1996","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.nbd.2012.04.004_bb0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1006\/exnr.1996.0175","article-title":"Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7","volume":"142","author":"Bartus","year":"1996","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0105","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1126\/science.281.5380.1161","article-title":"Sustained delivery of proteins for novel therapeutic agents","volume":"281","author":"Bartus","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.nbd.2012.04.004_bb0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/107175499267110","article-title":"Use of Cereport (RMP-7) to increase delivery of carboplatin to gliomas: insight and parameters for intracarotid infusion via a single-lumen cannula","volume":"6","author":"Bartus","year":"1999","journal-title":"Drug Del."},{"key":"10.1016\/j.nbd.2012.04.004_bb0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1006\/exnr.1999.7247","article-title":"Evidence that Cereport's ability to increase permeability of rat gliomas is dependent upon extent of tumor growth: implications for treating newly emerging tumor colonies","volume":"161","author":"Bartus","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0080","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.npp.1300274","article-title":"Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1month in rats","volume":"28","author":"Bartus","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nbd.2012.04.004_bb0075","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1124\/jpet.103.064121","article-title":"A pulmonary formulation of l-dopa enhances its effectiveness in a rat model of Parkinson's disease","volume":"310","author":"Bartus","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl. 3","key":"10.1016\/j.nbd.2012.04.004_bb0065","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S1353-8020(08)70052-X","article-title":"Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point","volume":"13","author":"Bartus","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nbd.2012.04.004_bb0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2011.05.026","article-title":"Properly scaled and targeted AAV-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease","volume":"44","author":"Bartus","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2012.04.004_bb0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.23442","article-title":"Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains","volume":"26","author":"Bartus","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2012.04.004_bb0700","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1474-4422(10)70256-8","article-title":"Reflection and reaction: gene therapy for Parkinson's disease: do we have the cure?","volume":"9","author":"Benabid","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/exnr.2000.7409","article-title":"Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF","volume":"164","author":"Bensadoun","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0595","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(00)02915-2","article-title":"Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model","volume":"886","author":"Bjorklund","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2012.04.004_bb0600","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0006-2952(98)00280-9","article-title":"A commentary on glial cell line-derived neurotrophic factor (GDNF). From a glial secreted molecule to gene therapy","volume":"57","author":"Bohn","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0170","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-8993(90)90985-K","article-title":"Peripheral administration of a long-chain fatty alcohol promotes septal cholinergic neurons survival after fimbria\u2013fornix transection","volume":"518","author":"Borg","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2012.04.004_bb0175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0304-3940(99)00208-6","article-title":"Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry","volume":"265","author":"Braak","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2012.04.004_bb0180","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.nbd.2012.04.004_bb0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0006-8993(96)00398-8","article-title":"Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate","volume":"728","author":"Charles","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2012.04.004_bb0190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/exnr.1998.6887","article-title":"Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor","volume":"154","author":"Choi-Lundberg","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0195","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/exnr.1997.6448","article-title":"Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor","volume":"145","author":"Day-Lollini","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0200","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.neuro.31.061307.090711","article-title":"Role of axonal transport in neurodegenerative diseases","volume":"31","author":"De Vos","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"issue":"Suppl. 14","key":"10.1016\/j.nbd.2012.04.004_bb0205","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1002\/mds.20957","article-title":"Deep brain stimulation: postoperative issues","volume":"21","author":"Deuschl","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2012.04.004_bb0210","first-page":"3998","article-title":"Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors","volume":"56","author":"Elliott","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.nbd.2012.04.004_bb0215","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-200140020-00003","article-title":"The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood\u2013brain barrier: from concept to clinical evaluation","volume":"40","author":"Emerich","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.nbd.2012.04.004_bb0220","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000017069","article-title":"Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease","volume":"9","author":"Eriksdotter Jonhagen","year":"1998","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.nbd.2012.04.004_bb0225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/329065a0","article-title":"Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor","volume":"329","author":"Fischer","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2012.04.004_bb0230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.8420006","article-title":"Blood\u2013brain barrier penetration and in vivo activity of an NGF conjugate","volume":"259","author":"Friden","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.nbd.2012.04.004_bb0235","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cne.903630302","article-title":"Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys","volume":"363","author":"Gash","year":"1995","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0240","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/380252a0","article-title":"Functional recovery in parkinsonian monkeys treated with GDNF","volume":"380","author":"Gash","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2012.04.004_bb0245","unstructured":"Gasmi, M., et al., 2012. Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of same. US Patent # 8092429 B2 Jan 10, 2012."},{"key":"10.1016\/j.nbd.2012.04.004_bb0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nbd.2007.04.003","article-title":"AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease","volume":"27","author":"Gasmi","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2012.04.004_bb0255","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/sj.mt.6300010","article-title":"Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease","volume":"15","author":"Gasmi","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0260","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1523\/JNEUROSCI.1122-04.2004","article-title":"Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system","volume":"24","author":"Georgievska","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0265","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2012.04.004_bb0270","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/mt.2010.106","article-title":"Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC","volume":"18","author":"Hadaczek","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0275","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0197-4580(89)90118-8","article-title":"Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases","volume":"10","author":"Hefti","year":"1989","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.nbd.2012.04.004_bb0295","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/mds.21503","article-title":"Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys","volume":"22","author":"Herzog","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2012.04.004_bb0290","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2008.170","article-title":"Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum","volume":"16","author":"Herzog","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0285","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1227\/01.NEU.0000340682.06068.01","article-title":"Expression, bioactivity, and safety 1year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support CERE-120 for Parkinson's disease","volume":"64","author":"Herzog","year":"2009","journal-title":"Neurosurgery"},{"key":"10.1016\/j.nbd.2012.04.004_bb0605","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s13346-011-0037-z","article-title":"Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically-active neurotrophic factor proteins for neurodegenerative diseases","volume":"1","author":"Herzog","year":"2011","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.nbd.2012.04.004_bb0610","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0304-3940(94)90218-6","article-title":"Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo","volume":"182","author":"Hoffer","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2012.04.004_bb0305","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/01926230701481899","article-title":"Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys)","volume":"35","author":"Hovland","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0310","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","article-title":"Neurotrophins: roles in neuronal development and function","volume":"24","author":"Huang","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0315","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3171\/jns.1994.81.5.0752","article-title":"Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors","volume":"81","author":"Inamura","year":"1994","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.nbd.2012.04.004_bb0320","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1021\/jm00100a020","article-title":"Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists","volume":"35","author":"Jacobson","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.nbd.2012.04.004_bb0615","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archpsyc.1989.01810110061009","article-title":"Hippocampal pathologic findings in schizophrenia. A morphometric study","volume":"46","author":"Jeste","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.nbd.2012.04.004_bb0330","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000017069","article-title":"Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease","volume":"9","author":"Jonhagen","year":"1998","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.nbd.2012.04.004_bb0335","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1046\/j.1460-9568.2000.00274.x","article-title":"Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor","volume":"12","author":"Kirik","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0340","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1523\/JNEUROSCI.20-12-04686.2000","article-title":"Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system","volume":"20","author":"Kirik","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0345","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrc1122","article-title":"Occurrence of leukaemia following gene therapy of X-linked SCID","volume":"3","author":"Kohn","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.nbd.2012.04.004_bb0370","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cne.902770402","article-title":"Nerve growth factor receptor immunoreactivity in the nonhuman primate (Cebus apella): distribution, morphology, and colocalization with cholinergic enzymes","volume":"277","author":"Kordower","year":"1988","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0365","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1073\/pnas.91.19.9077","article-title":"Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease","volume":"91","author":"Kordower","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2012.04.004_bb0360","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","article-title":"Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease","volume":"46","author":"Kordower","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0355","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.nbd.2012.04.004_bb0350","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","article-title":"Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys","volume":"60","author":"Kordower","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0375","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/384467a0","article-title":"Neurturin, a relative of glial-cell-line-derived neurotrophic factor","volume":"384","author":"Kotzbauer","year":"1996","journal-title":"Lett. Nat."},{"key":"10.1016\/j.nbd.2012.04.004_bb0380","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0385","first-page":"592","article-title":"Protection of mouse photoreceptors by survival factors in retinal degenerations","volume":"39","author":"LaVail","year":"1998","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0390","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.23544","article-title":"Parkinson's disease, primates, and gene therapy: vive la difference?","volume":"26","author":"Lewis","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2012.04.004_bb0395","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1021\/jm00074a031","article-title":"Peptide alpha-keto ester, alpha-keto amide, and alpha-keto acid inhibitors of calpains and other cysteine proteases","volume":"36","author":"Li","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.nbd.2012.04.004_bb0400","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jps.2600830112","article-title":"Adenosine receptor prodrugs: synthesis and biological activity of derivatives of potent, A1-selective agonists","volume":"83","author":"Maillard","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0405","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/mt.2009.196","article-title":"Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector","volume":"17","author":"Manfredsson","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0410","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/mt.2009.45","article-title":"Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity","volume":"17","author":"Manfredsson","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0420","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0415","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0425","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/156652311795684759","article-title":"Adeno-associated virus (AAV) vectors in the CNS","volume":"11","author":"McCown","year":"2011","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0430","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3727\/096020198389988","article-title":"Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion","volume":"11","author":"McGrath","year":"2002","journal-title":"Cell Transplant."},{"key":"10.1016\/j.nbd.2012.04.004_bb0435","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1098\/rstb.1996.0039","article-title":"NGF as a mediator of inflammatory pain","volume":"351","author":"McMahon","year":"1996","journal-title":"Philos. Trans. R. Soc. Lond. B, Biol. Sci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0440","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.410390215","article-title":"A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis","volume":"39","author":"Miller","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0445","doi-asserted-by":"crossref","first-page":"12776","DOI":"10.1523\/JNEUROSCI.3463-09.2009","article-title":"Axonal transport defects in neurodegenerative diseases","volume":"29","author":"Morfini","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0450","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3171\/JNS-07\/07\/0074","article-title":"Convective delivery of glial cell line-derived neurotrophic factor in the human putamen","volume":"107","author":"Morrison","year":"2007","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.nbd.2012.04.004_bb0455","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0301-0082(98)00059-8","article-title":"Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases","volume":"57","author":"Mufson","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0460","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3171\/jns.1999.91.3.0447","article-title":"Intraventricular infusion of nerve growth factor as the cause of sympathetic fiber sprouting in sensory ganglia","volume":"91","author":"Nauta","year":"1999","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.nbd.2012.04.004_bb0465","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","article-title":"Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD","volume":"60","author":"Nutt","year":"2003","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.nbd.2012.04.004_bb0620","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/j.1530-0277.1999.tb04071.x","article-title":"Crews FT. Suppression of alcohol intake by chronic Naloxone treatment in P rats: tolerance development and elevation of opiate receptor binding","volume":"23","author":"Overstreet","year":"1999","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.nbd.2012.04.004_bb0475","first-page":"66","article-title":"Selective transport of an anti-transferrin receptor antibody through the blood\u2013brain barrier in vivo","volume":"259","author":"Pardridge","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0625","first-page":"94","article-title":"Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial)","volume":"40","author":"Penn","year":"1997","journal-title":"Neurosurgery"},{"key":"10.1016\/j.nbd.2012.04.004_bb0485","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.neuro.29.051605.112929","article-title":"Neurotrophins: mediators and modulators of pain","volume":"29","author":"Pezet","year":"2006","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0490","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.1068613","article-title":"Axonal self-destruction and neurodegeneration","volume":"296","author":"Raff","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.nbd.2012.04.004_bb0495","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.nbd.2012.04.004_bb0500","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1460-9568.2003.02456.x","article-title":"Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system","volume":"17","author":"Rosenblad","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0505","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-004-0952-x","article-title":"Axonal transport defects: a common theme in neurodegenerative diseases","volume":"109","author":"Roy","year":"2005","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0630","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.expneurol.2006.07.015","article-title":"Point source concentration of GDNF may explain failure of phase II clinical trial","volume":"202","author":"Salvatore","year":"2006","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.nbd.2012.04.004_bb0515","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.103.049700","article-title":"Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic-acid induced neurodegeneration","volume":"306","author":"Salzberg-Brenhouse","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0520","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0079-6468(08)70081-X","article-title":"Discovery of CEP-1347\/KT-7515, an inhibitor of the JNK\/SAPK pathway for the treatment of neurodegenerative diseases","volume":"40","author":"Saporito","year":"2002","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.nbd.2012.04.004_bb0525","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0166-4328(93)90141-C","article-title":"Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy","volume":"57","author":"Seiger","year":"1993","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.nbd.2012.04.004_bb0530","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1523\/JNEUROSCI.19-12-05034.1999","article-title":"Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression","volume":"19","author":"Sheline","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0535","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.20861","article-title":"Crossroads in GDNF therapy for Parkinson's disease","volume":"21","author":"Sherer","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2012.04.004_bb0540","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","article-title":"Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor","volume":"102","author":"Slevin","year":"2005","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.nbd.2012.04.004_bb0635","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.410260402","article-title":"Neurotrophic molecules","volume":"26","author":"Snider","year":"1989","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2012.04.004_bb0550","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1146\/annurev.neuro.24.1.1217","article-title":"Nerve growth factor signaling, neuroprotection, and neural repair","volume":"24","author":"Sofroniew","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2012.04.004_bb0555","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1089\/hum.2009.103","article-title":"Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys","volume":"20","author":"Su","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0565","first-page":"305","article-title":"Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration","volume":"3","author":"Tuszynski","year":"1996","journal-title":"Gene Ther."},{"key":"10.1016\/j.nbd.2012.04.004_bb0640","first-page":"1","article-title":"A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease","author":"Tuszynski","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2012.04.004_bb0645","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1212\/01.wnl.0000324506.93877.5e","article-title":"Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease","volume":"71","author":"Wang","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2012.04.004_bb0575","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1529-8027.2001.01019.x","article-title":"A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy","volume":"6","author":"Wellmer","year":"2001","journal-title":"J. Peripher. Nerv. Syst."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996112001337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996112001337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T06:34:58Z","timestamp":1561617298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996112001337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0969996112001337"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2012.04.004","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}